Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVAT-121 Phase 1 Study in Healthy Adults
NCT07918469Phase 1Not yet recruiting
- Sponsor
- Avata Biosciences
- Start
- Oct 2026
- Primary completion
- Mar 2027
01
Overview
Phase 1, open-label trial of cannabidiol in Focal onset seizure (3 arms), sponsored by Avata Biosciences. Primary endpoints: Treatment-Emergent Adverse Events at Day 31, Serious Adverse Events at Day 31 and 4 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
Focal onset seizure
Beyond the preview
Go deeper on NCT07918469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07918469.